Risk Stratification in Lean MA... Note

Risk Stratification in Lean MASLD

Evaluation of metabolic dysfunction–associated steatotic liver disease (MASLD) relies on the “visible proxy” of body size. This is understandable: excess adiposity, associated with insulin resistance, type 2 diabetes, and cardiometabolic dysfunction, is a major driver of the global MASLD epidemic. Yet this framing becomes misleading when body mass index (BMI) is treated as a surrogate for metabolic risk. A clinically important minority of patients develop MASLD despite a BMI in the normal range. These patients, commonly described as having lean MASLD, reveal the limitations of an obesity-centered clinical approach and ultimately challenge the assumption that normal body weight implies low liver-related risk.